2019

1. Verma N and Despa F, Contributing Factors to Diabetic Brain Injury and Cognitive Decline. Diabetes Metab J. 2019. 5:560-567. doi: 10.4093/dmj.2019.0153.

2. Ly H, Verma N, Lashley T, et al. Amylin dyshomeostasis disrupts white matter structural integrity and modulates amyloid composition and pathology distribution in brains of patients with AD and AD rats. Alzheimers Dement. 2019.

3. Ly H, Kotiya D, Despa F, Genetic Manipulation of Amylin Dramatically Accelerates Aging and Behavioral Changes in AD Rats. Alzheimers Dement. 2019

4. Verma N*, Liu M*, Ly H, et al., Diabetic Microcirculatory Disturbances and Pathologic Erythropoiesis Provoked by Deposition of Amyloid-Forming Amylin in Red Blood Cells and Capillaries. Kidney Int. 2019. (*: co-authors).

5. Ly H and Despa F, Diabetes-related amylin dyshomeostasis–a contributing factor to cerebrovascular pathology and dementia. J Lipid Atheroscelr. 2019. doi 10.12997/jla.2019.8.e9.

6. Popescu I, Yin G, Velmurugan S, et al., Lower sarcoplasmic reticulum Ca2+ threshold for triggering afterdepolarizations in diabetic rat hearts. Heart Rhythm. 2019. doi: 10.1016/j.hrthm.2018.11.001.

7. De Rossi P, Andrew RJ, Musial TF, et al., Aberrant accrual of BIN1 near Alzheimer's disease amyloid deposits in transgenic models. Brain Pathol. 2018. 71:65-74.

 

2018

1. Ly H, Verma N, Wu F, et al., Amylin Dyshomeostasis – a Non-Alzheimer’s Disease Process Contributing to an Alzheimer’s Disease Phenotype. Alzheimers Dement. 2018.14(7): P696-697.

2. Kotiya D, Ly H, Chen L, et al., CSF Amylin: Effect Modifier of the Aβ-AD Relationship. Alzheimers Dement. 2018. 14(7): P772-773.

3. Despa F, Biessels GJ. Cognitive decline and dementia in diabetes mellitus: mechanisms and clinical implications. Nat Rev Endocrinol. 2018. doi: 10.1038/s41574-018-0048-7.

4. Stewart BD, Scott CE, McCoy TP, et al, Computational modeling of amylin-induced calcium dysregulation in rat ventricular cardiomyoctes. Cell Calcium. 2018. 71:65-74.

5. Liu M, Hoskins A, Verma N, et al. Amylin and diabetic cardiomyopathy-amylin-induced sacrolemmal Ca2+ leak is independent of diabetic remodeling of myocardium. Biochim Biophys Acta. 2018. 1864(5 Pt B):1923-1930.

 

2017 

1. Ly H, Verma N, Wu F, et al., Brain microvascular injury and white matter disease provoked by diabetes-associated hyperamylinemia. Ann Neurol. 2017. 82, 208-222.

2. 1.    Ly H., Verma N., Wu F., et al. Diabetes-Associated Amylin Dyshomeostasis Provokes Brain White Matter Disease And Behavior Changes: An Animal Model. Alzheimers Dement. 2017. 13(7): P635. 

3. Van Steenbergen A, Balteau M, Ginion A,et al., Sodium-myoinositol cotransporter-1, SMIT1, mediates the production of reactive oxygen species induced by hyperglycemia in the heart. Sci Rep. 2017. 7:41166.

 

2016

1. Liu M, Verma N, Peng X, et al., Hyperamylinemia increases IL-1β synthesis in the heart via peroxidative sarcolemmal injury. Diabetes. 2016. 65, 2772-83.

2. Verma N, Ly H, Liu M, et al., Intraneuronal Amylin Deposition, Peroxidative Membrane Injury and Increased IL-1β Synthesis in Brains of Alzheimer's Disease Patients with Type-2 Diabetes and in Diabetic HIP Rats. J Alzheimers Dis. 2016. 5;53(1):259-72.

3. Ilaiwy A, Liu M, Parry TL, et al., Human amylin proteotoxicity impairs protein biosynthesis, and alters major cellular signaling pathways in the heart, brain and liver of humanized diabetic rat model in vivo. Metabolomics. 2016. 12(5). pii: 95.

 

2015

1. Ly H, Despa F. Hyperamylinemia as a risk factor for accelerated cognitive decline in diabetes. Expert Rev Proteomics. 2015.12(6):575-7

2. Lambert R, Srodulski S, Peng X, et al., Intracellular Na+ Concentration ([Na+]i) Is Elevated in Diabetic Hearts Due to Enhanced Na+-Glucose Cotransport. J Am Heart Assoc. 2015. 27;4(9):e002183

3. Guan H, Chow KM, Song E, et al., The Mitochondrial Peptidase Pitrilysin Degrades Islet Amyloid Polypeptide in Beta-Cells. PLoS One. 2015. 20;10(7):e0133263

 

2014 

1. Srodulski S, Sharma S, Bachstetter AB, Brelsfoard JM, Pascual C, Xie XS, Saatman KE, Van Eldik LJ, Despa F. Neuroinflammation and neurologic deficits in diabetes linked to brain accumulation of amylin. Mol Neurodegener. 2014. 22;9:30.

2. Despa S, Sharma S, Harris TR, Dong H, Li N, Chiamvimonvat N, Taegtmeyer H, Margulies KB, Hammock BD, Despa F. Cardioprotection by controlling hyperamylinemia in a "humanized" diabetic rat model. J Am Heart Assoc. 2014. 21;3(4).

 

2013 

1. Despa F, Decarli C. Amylin: what might be its role in Alzheimer's disease and how could this affect therapy? Expert Rev Proteomics. 2013. 10(5):403-5.

2. Erickson JR, Pereira L, Wang L, et al., Diabetic Hyperglycemia activates CaMKII and Arrhythmias by O linked Glycosylation. Nature. 2013. 502:372-6.

3. Jackson K, Barisone GA, Diaz E, et al., Amylin deposition in the brain: a second amyloid in Alzheimer’s disease? Ann Neurol. 2013. 74: 517-26.

 

2012 

1. Guglielmino K, Jackson K, Harris TR, et al., Pharmacological inhibition of soluble epoxide hydrolase provides cardioprotection in hyperglycemic rats. Am J Physiol Heart Circ Physiol. 2012. 303(7):H853-62.

2. Despa S, Margulies K, Chen L, et al., Hyperamylinemia contributes to cardiac dysfunction in obesity and diabetes- a study in humans and rats, Circ. Res. 2012. 110: 598-608.